52 Week Range
As of on the Over The Counter ∙ Minimum 15 minute delay
Bioqual Inc:Declares dividend of $0.20 per share for shareholders of record on Nov. 28, payable on Dec. 15.
Bioqual Inc announced that in view of current considerations, the Board of Directors determined not to declare a dividend for Fiscal Year 2013.
BIOQUAL, Inc., announced that it has filed Form 15 with the SEC.
BIOQUAL, Inc. announced that it was awarded a five-year, $21.2 million dollar renewal contract by the National Institute of Child Health and Human Development (NICHD), National Institutes of Health, to continue to support a broad spectrum of research in contraception and reproductive health. Effective January 19, 2002, the five-year contract totals $21,195,867 with $3,989,309 budgeted for the first year.
BIOQUAL, Inc. announced that the NCI renewed its contract to support cancer researchers at the National Cancer Institute (NCI) of the National Institutes of Health (NIH). The contract entitled Facility for Breeding, Housing and Handling Virus Infected Mice is for a base year and four option years for a total of $13,740,310. The renewal combines two current contracts with the NCI's Experimental Immunology Branch. Under the new contract BIOQUAL will house up to 17,000 mice and will conduct an extensive breeding and testing program to support approximately thirty-five NCI scientists who are conducting basic immunological research.
BIOQUAL, Inc. announced that it has been awarded a two-year Phase II SBIR grant, effective September 30, 2001, entitled "Comparative DNA Sequence Variation In Alzheimer Genes" for $738,847. BIOQUAL scientists will use biochemical assays to identify aged, living chimpanzees with dementia or other aging-related disorders. BIOQUAL scientists will then search for disease-causing mutations in those individuals, as well as in archival chimpanzee brain tissues having AD-related neuropathology, at five AD-related genes.
BIOQUAL, Inc. announced that it began a contract to support the recently established National Institutes of Health (NIH) Virus Research Center (VRC). The contract entitled Housing and Maintenance of Nonhuman Primates for the Vaccine Research Center totals $8,230,253 and will operate for seven years to February 2008. The purpose of the VRC is to integrate modern immunological science with detailed understanding of the pathogenesis of AIDS infection, development of immunogens and vectors, and new approaches to vaccination.
BIOQUAL, Inc. renewed its contract to support AIDS researchers at the National Cancer Institute (NCI) of the National Institutes of Health (NIH). The contract entitled Nonhuman Primate Models of AIDS: Prophylactic and Therapeutic Studies totals $4,628,783 and will operate for five years to December 2005.
BIOQUAL, Inc. announced that it has been awarded a $99,153 Phase I grant from the National Institutes of Health as part of its Small Business Innovation Research program. The six month grant is to identify and characterize DNA sequence variation in chimpanzees at four genes that contain mutations implicated in the pathogenesis of Alzheimer's Disease.
BIOQUAL, Inc. renewed its contract to support infectious disease researchers at the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. The contract, entitled Facility for Animals Used in Infectious Disease Research, totals $6,298,647 and extends for seven years to February 2007.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.